Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels

被引：28

作者：

Canale, Maria Laura ^{[1
]}

Bisceglia, Irma ^{[2
]}

Lestuzzi, Chiara ^{[3
]}

Parrini, Iris ^{[4
]}

机构：

[1] Osped Versilia, Azienda USL Toscana Nord Ovest, Div Cardiol, Lido Di Camaiore, Italy

[2] Azienda Osped San Camillo Forlanini, Integrated Cardiol Serv, Rome, Italy

[3] Natl Canc Inst, CRO, Oncol Dept, Cardiol Unit, Aviano, Italy

[4] Osped Mauriziano Umberto 1, Div Cardiol, Turin, Italy

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 09期

关键词：

Arterial thrombosis; chemotherapy; radiotherapy; angiogenesis; review; TYROSINE KINASE INHIBITORS; TRANSIENT ISCHEMIC ATTACK; ENDOTHELIAL GROWTH-FACTOR; THROMBOEMBOLIC EVENTS; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK; STROKE; TOXICITY; TUMORS;

D O I：

10.21873/anticanres.13642

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer patients are at risk for both venous and arterial thrombotic events. Accumulating evidence suggests a link between cancer and arterial thrombosis events. The pathophysiology of arterial thrombosis in cancer is complex and multifactorial. The risk of arterial thrombosis in cancer patients relies on individual risk factors, on cancer-related hypercoagulability, on anticancer drugs and radiotherapy often via a common underlying mechanism of endothelial dysfunction. This review describes the mechanisms involved in the development of arterial thrombotic events and their clinical manifestations. Furthermore, it provides an overview on therapeutic agents associated with arterial thrombosis.

引用

页码：4619 / 4625

页数：7

共 49 条

[1] Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis [J].

Abdel-Qadir, Husam ;

Ethier, Josee-Lyne ;

Lee, Douglas S. ;

Thavendiranathan, Paaladinesh ;

Amir, Eitan .

CANCER TREATMENT REVIEWS, 2017, 53 :120-127

[2] Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents [J].

Abdel-Rahman, Omar ;

ElHalawani, Hesham .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 102 :89-100

[3] Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis [J].

Abdel-Rahman, Omar ;

Fouad, Mona .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 92 (03) :194-207

[4] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis [J].

Amir, Eitan ;

Seruga, Bostjan ;

Niraula, Saroj ;

Carlsson, Lindsay ;

Ocana, Alberto .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) :1299-1309

[5] Arterial and Venous Thrombosis in Cancer Patients [J].

Blann, Andrew D. ;

Dunmore, Simon .

CARDIOLOGY RESEARCH AND PRACTICE, 2011, 2011

[6] RADIATION HEART-DISEASE - ANALYSIS OF 16 YOUNG (AGED 15 TO 33 YEARS) NECROPSY PATIENTS WHO RECEIVED OVER 3,500 RADS TO THE HEART [J].

BROSIUS, FC ;

WALLER, BF ;

ROBERTS, WC .

AMERICAN JOURNAL OF MEDICINE, 1981, 70 (03) :519-530

[7] Risk of regorafenib-induced cardiovascular events in patients with solid tumorsA systematic review and meta-analysis A systematic review and meta-analysis [J].

Chen, Jianxin ;

Wang, Junhui .

MEDICINE, 2018, 97 (41)

[8] Lung Cancer and Incidence of Stroke A Population-Based Cohort Study [J].

Chen, Pei-Chun ;

Muo, Chih-Hsin ;

Lee, Yuan-Teh ;

Yu, Yang-Hao ;

Sung, Fung-Chang .

STROKE, 2011, 42 (11) :3034-3039

[9] Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors [J].

Chopade, Pradnya ;

Akard, Luke P. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (11) :710-723

[10] Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials [J].

Choueiri, Toni K. ;

Schutz, Fabio A. B. ;

Je, Youjin ;

Rosenberg, Jonathan E. ;

Bellmunt, Joaquim .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2280-2285

← 1 2 3 4 5 →